Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Emgality Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
Historical expansion was driven by elevated rates of migraine occurrence, persistent gaps in chronic migraine treatment, the successful clinical outcomes of CGRP-targeted therapies, neurologists’ increasing acceptance of biologic drugs, and heightened recognition in diagnosis.
The anticipated growth during the forecast period is primarily due to an expanding chronic migraine population, the inclusion of new headache indications, increasing acceptance of biologic drugs, improved patient adherence, and a rise in neurology healthcare spending.
Significant trends expected over the projected timeframe encompass the growing adoption of CGRP inhibitors, a shift towards preventive migraine therapies, an escalating demand for long-term headache control, the broadening use of biologic neurology treatments, and patients showing a preference for monthly injections.
Get A Free Sample Report With In-Depth Market Insights:
Emgality Market Growth Momentum: What Factors Are Shaping Demand?
The escalating occurrence of migraine is anticipated to propel the expansion of the emgality market in the future. Migraine is a neurological condition characterized by intense, throbbing headaches, frequently accompanied by symptoms such as nausea, heightened sensitivity to light and sound, and occasionally visual or sensory disturbances referred to as auras. The widespread presence of migraine is attributed to factors including rising stress levels, shifts in lifestyle, environmental catalysts, and improved awareness and diagnosis of the condition. Emgality functions by blocking the calcitonin gene-related peptide (CGRP) to prevent migraines, thereby diminishing the frequency and severity of attacks. This treatment delivers sustained relief, enhancing the quality of life and lessening migraine-related disability for frequent sufferers. For example, in May 2023, Migraine Canada, an organization supporting individuals affected by migraines, reported that migraines affect 12% of Canadians (4.5M) and over 1 billion globally. The prevalence is notably higher in women (30% lifetime) compared to men (8%) and children (10%), impacting one in four households, with 1-2% experiencing chronic migraines. Consequently, the increasing prevalence of migraine will drive the growth of the emgality market.
Emgality Market Segment Performance And Emerging Opportunities
The emgality market covered in this report is segmented –
1) By Clinical Indication: Migraine Prevention, Cluster Headaches
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Emgality Market Trends Redefining Industry Growth
A primary development within the emgality market involves the adoption of strategic partnership models, designed to improve technological integration and extend market presence. Such partnerships generally entail cooperative relationships among multiple organizations, pooling their respective resources, specialized knowledge, and efforts to reach shared aims or objectives. As an illustration, during December 2023, Organon & Co., a healthcare firm from the US specializing in women’s health, extended its collaboration with Eli Lilly. This expansion aimed to widen the availability of the innovative migraine therapies, Emgality and RAYVOW, across Europe, leveraging Organon’s proficiency in central nervous system conditions and its existing commercial infrastructure. This alliance specifically addresses the substantial burden of migraines on women and reinforces Organon’s offerings within the women’s health sector. Organon will be responsible for the distribution and promotion of these products, whereas Lilly will retain control over manufacturing and marketing authorization, thus guaranteeing the efficient provision of these vital treatments.
Emgality Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the emgality market are Eli Lilly and Company
View The Full Emgality Market Report:
Emgality Market Regional Analysis And Leading Geography
North America was the largest region in the emgality market in 2025. The regions covered in the emgality market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
